CN101687934A - 聚乙二醇化促红细胞生成素偶联物和其制备方法与用途 - Google Patents
聚乙二醇化促红细胞生成素偶联物和其制备方法与用途 Download PDFInfo
- Publication number
- CN101687934A CN101687934A CN200880021159A CN200880021159A CN101687934A CN 101687934 A CN101687934 A CN 101687934A CN 200880021159 A CN200880021159 A CN 200880021159A CN 200880021159 A CN200880021159 A CN 200880021159A CN 101687934 A CN101687934 A CN 101687934A
- Authority
- CN
- China
- Prior art keywords
- erythropoietin
- conjugate
- recombinant human
- integer
- human erythropoietin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (12)
- 权利要求书:1. 一种聚乙二醇化促红细胞生成素偶联物, 其结构通式为P-NH-CH2-X-S-Y- (OCH2CH2) mi-OCH3所述偶联物是由甲氧基聚乙二醇基团通过式 -CHrX-S-Y-中的 -CH2-基团与促红 细胞生成素的氨基形成 -NH-CH2-键连接而得到, 其中 P是指重组人促红细胞 生成素, X是 -(CH2)k -或 -CH2(OCH2CH2)k-, k的数目选自 2〜10的整数, ml 选自 100〜2000之间的整数, Y选自:其中 m、 n的数目各自独立地选自 2〜10的; 根据权利要求 1所述的偶联物, 其特征在于所述重组人促红细胞生成素是 重组人促红细胞生成素 α或 β, 优选重组人促红细胞生成素 α。 根据权利要求 1所述的偶联物, 其特征在于 Υ中的 m=2, n=2。 根据权利要求 1所述的偶联物, 其特征在于 X是 -(CH2)k-, k选自 2〜10 的整数, 优选 2〜4的整数, 最优选为 2。 根据权利要求 1所述的偶联物, 其特征在于所述甲氧基聚乙二醇基团的平 均分子量为 5, 000〜40, 000道尔顿, 优选为 20, 000道尔顿。
- 6. 根据权利要求 1所述的偶联物, 其特征在于偶联物的结构式为:其中 P是指重组人促红细胞生成素;X是 -(CH2)k-或 -CH2(OCH2CH2)k-, 优选是 -(C¾)k-;k的数目选自 2〜10的整数, 优选 2〜4的整数, 最优选为 2;m、 n选自 2〜10的整数;选自 100〜2000之间的整数。
- 7. 根据权利要求 1 所述的偶联物, 其特征在于偶联物的结构式其中 选自 450〜600的整数。
- 8. 根据权利要求 6所述的偶联物, 其特征在于所述重组人促红细胞生成素是 重组人促红细胞生成素 01或 , 优选重组人促红细胞生成素 α。
- 9. 根据权利要求 1所述的偶联物, 其结构式为-其中 P是指重组人促红细胞生成素, 优选重组人促红细胞生成素 α;X是 -(CH2)k-或 -C¾(OCH2CH2)k-;k的数目选自 2〜10的整数, 优选为 2;m选自 2〜10的整数, 优选为 2;选自 100〜2000之间的整数, 优选自 450〜600的整数。
- 10.根据权利要求 1所述的偶联物, 其结构式为:其中 P是指重组人促红细胞生成素, 优选是重组人促红细胞生成素 α; X是 -(CH2)k-或 -CH2(OCH2CH2)k-,优选是 X是 -(CH2)2-;k选自 2〜10的整数;m选自 2〜10, 优选为 2 ;选自 100〜2000之间的整数, 优选自 450〜600的整数。
- 11.根据权利要求 1所述的偶联物, 其特征在于偶联物的结构式为:其中 P是指重组人促红细胞生成素, 优选是重组人促红细胞生成素 α; X是- (CH2)k-或 -C¾(OCH2C¾)k-,优选是 X是 -(C¾)2-;k选自 2〜10的整数;Π 选自 100〜2000之间的整数, 优选自 450〜600的整数。 12. 根据权利要求 1所述的偶联物, 其特征在于偶联物的结构式为:其中 P是指重组人促红细胞生成素, 优选是重组人促红细胞生成素 α;X是 -(C¾)k-或 -CH2(OCH2CH2)k-,优选是 X是 -(CH2)2-;k的数目选自 2〜10的整数;m选自 2〜10的整数, 优选为 2;选自 100〜2000之间的整数, 优选自 450〜600的整数。
- 13.根据权利要求 1所述的偶联物, 其结构式为:其中 P是指重组人促红细胞生成素, 优选是重组人促红细胞生成素 α;X是 -(CH2)k-或 -CH2(OCH2CH2)k-,优选是 X是 -(C¾)2-;k的数目选自 2〜10的整数;m、 n选自 2〜10的整数, 优选为 2;选自 100〜2000之间的整数, 选自 450〜600的整数。
- 14.一种制备权利要求 1〜13任意一项所述偶联物的方法, 包括以下步骤- ( 1 )促红细胞生成素和含有已保护巯基的醛类物质发生还原胺化反应,形成 通过 -NH-CH2-键连接的活化促红细胞生成素;(2)所述活化促红细胞生成素脱保护, 与活性甲氧基聚乙二醇衍生物偶联。
- 15.一种药物组合物, 包含:( 1 ) 治疗量的如权利要求 1〜13任意一项所述的聚乙二醇化促红细胞生成 素偶联物, 和(2)药学可接受的药物载体。
- 16.根据权利要求 1〜13任意一项所述的偶联物在制备用于治疗以缺乏红细胞 生成素或红细胞群缺少或缺陷为特征的疾病的药物中的用途。
- 17.根据权利要求 15所述的药物组合物在制备用于治疗以缺乏红细胞生成素 或红细胞群缺少或缺陷为特征的疾病的药物中的用途。 18.根据权利要求 16或 17所述的用途, 其特征在于缺乏红细胞生成素或红细 胞群缺少或缺陷为特征的疾病是末期肾功能衰竭或透析; AIDS相关性贫 血, 自身免疫性疾病, 或恶性肿瘤; 囊性纤维变性; 早期早熟性贫血; 与 慢性炎性疾病相关的贫血; 脊髓损伤; 急性失血; 衰老和伴有异常红细胞 产生的肿瘤疾病。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008800211594A CN101687934B (zh) | 2007-12-10 | 2008-11-25 | 聚乙二醇化促红细胞生成素偶联物和其制备方法与用途 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007101953118A CN101455844B (zh) | 2007-12-10 | 2007-12-10 | 聚乙二醇化促红细胞生成素偶联物和其制备方法与用途 |
CN200710195311.8 | 2007-12-10 | ||
CN2008800211594A CN101687934B (zh) | 2007-12-10 | 2008-11-25 | 聚乙二醇化促红细胞生成素偶联物和其制备方法与用途 |
PCT/CN2008/001921 WO2009079911A1 (fr) | 2007-12-10 | 2008-11-25 | Conjugué d'érythropoïétine pégylée et procédé de préparation et utilisations |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101687934A true CN101687934A (zh) | 2010-03-31 |
CN101687934B CN101687934B (zh) | 2012-07-25 |
Family
ID=40767143
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007101953118A Active CN101455844B (zh) | 2007-12-10 | 2007-12-10 | 聚乙二醇化促红细胞生成素偶联物和其制备方法与用途 |
CN2008800211594A Active CN101687934B (zh) | 2007-12-10 | 2008-11-25 | 聚乙二醇化促红细胞生成素偶联物和其制备方法与用途 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007101953118A Active CN101455844B (zh) | 2007-12-10 | 2007-12-10 | 聚乙二醇化促红细胞生成素偶联物和其制备方法与用途 |
Country Status (4)
Country | Link |
---|---|
CN (2) | CN101455844B (zh) |
HK (1) | HK1136838A1 (zh) |
TW (1) | TWI430811B (zh) |
WO (1) | WO2009079911A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102838677A (zh) * | 2010-04-09 | 2012-12-26 | 苏州元基生物技术有限公司 | 重组促红细胞生成素及制备方法 |
CN103044539A (zh) * | 2010-04-09 | 2013-04-17 | 苏州元基生物技术有限公司 | 重组促红细胞生成素及制备方法 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101455844B (zh) * | 2007-12-10 | 2011-09-14 | 江苏豪森药业股份有限公司 | 聚乙二醇化促红细胞生成素偶联物和其制备方法与用途 |
KR20160111964A (ko) * | 2014-01-29 | 2016-09-27 | 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 | 리간드-세포독성 약물 접합체, 이의 제조방법 및 이의 용도 |
KR102268647B1 (ko) * | 2017-06-12 | 2021-06-23 | 한국코러스 주식회사 | 안정성이 향상된 에리스로포이에틴 조성물 및 이의 제조방법 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ244778A (en) * | 1991-10-21 | 1994-03-25 | Ortho Pharma Corp | Peg imidates and protein derivatives thereof |
PE20010288A1 (es) * | 1999-07-02 | 2001-03-07 | Hoffmann La Roche | Derivados de eritropoyetina |
US6956135B2 (en) * | 2001-12-11 | 2005-10-18 | Sun Bio, Inc. | Monofunctional polyethylene glycol aldehydes |
CN100362019C (zh) * | 2004-03-02 | 2008-01-16 | 成都生物制品研究所 | 聚乙二醇修饰后具有体内生理活性的重组促红细胞生成素 |
CN101455844B (zh) * | 2007-12-10 | 2011-09-14 | 江苏豪森药业股份有限公司 | 聚乙二醇化促红细胞生成素偶联物和其制备方法与用途 |
-
2007
- 2007-12-10 CN CN2007101953118A patent/CN101455844B/zh active Active
-
2008
- 2008-07-03 TW TW097125013A patent/TWI430811B/zh not_active IP Right Cessation
- 2008-11-25 WO PCT/CN2008/001921 patent/WO2009079911A1/zh active Application Filing
- 2008-11-25 CN CN2008800211594A patent/CN101687934B/zh active Active
-
2010
- 2010-05-11 HK HK10104546.9A patent/HK1136838A1/xx not_active IP Right Cessation
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102838677A (zh) * | 2010-04-09 | 2012-12-26 | 苏州元基生物技术有限公司 | 重组促红细胞生成素及制备方法 |
CN103044539A (zh) * | 2010-04-09 | 2013-04-17 | 苏州元基生物技术有限公司 | 重组促红细胞生成素及制备方法 |
CN103044539B (zh) * | 2010-04-09 | 2014-10-22 | 苏州元基生物技术有限公司 | 重组促红细胞生成素及制备方法 |
CN102838677B (zh) * | 2010-04-09 | 2014-10-22 | 苏州元基生物技术有限公司 | 重组促红细胞生成素及制备方法 |
Also Published As
Publication number | Publication date |
---|---|
HK1136838A1 (en) | 2010-07-09 |
CN101455844B (zh) | 2011-09-14 |
WO2009079911A1 (fr) | 2009-07-02 |
TW201002350A (en) | 2010-01-16 |
TWI430811B (zh) | 2014-03-21 |
CN101455844A (zh) | 2009-06-17 |
CN101687934B (zh) | 2012-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100510624B1 (ko) | 폴리에틸렌글리콜과의 에리트로포이에틴 결합체 | |
KR100593143B1 (ko) | 에리트로포이에틴 컨쥬게이트 | |
CN102234310B (zh) | 一种聚乙二醇修饰蛋白的分离纯化方法 | |
EP2233504B1 (en) | An erythropoietin mimetic peptide derivatives and its pharmaceutical salt, the preparation and uses thereof | |
US8901277B2 (en) | Interferon alpha mutant and its polyethylene glycol derivative | |
CN101703760A (zh) | 用于预防和治疗贫血的方法以及组合物 | |
CN101687934A (zh) | 聚乙二醇化促红细胞生成素偶联物和其制备方法与用途 | |
CN109963597B (zh) | 聚乙二醇化血管内皮抑制素类似物及其应用 | |
CN102153643A (zh) | 粒细胞集落形成刺激因子(g-csf)的突变体及其化学缀合多肽 | |
JP5458416B2 (ja) | 二本鎖ポリエチレングリコール化成長ホルモン、その製造方法およびその使用 | |
CN105820232A (zh) | 单修饰聚乙二醇重组人促红素的制备方法及其制品和应用 | |
CN101491682A (zh) | 聚乙二醇化重组人干扰素ω偶合物及其制备工艺 | |
JP5225393B2 (ja) | 水溶性高分子修飾g−csf複合体 | |
CN101163716A (zh) | 白细胞介素-6聚乙二醇结合物及其制备方法和应用 | |
RU2215748C2 (ru) | Способ получения рекомбинантного эритропоэтина человека и полученный эритропоэтин, фармацевтическая композиция | |
CN1169827C (zh) | 一种增强多肽在体内稳定性药物的生产方法及其应用 | |
KR20040083268A (ko) | 안정성이 증가된 인간 과립구 콜로니 자극인자 융합체 및이의 제조방법 | |
KR100353392B1 (ko) | 높은 생체 활성도를 갖는 생체 활성 단백질과 peg의결합체 제조방법 | |
WO2019088608A1 (ko) | 콜로니자극인자와 폴리올이 접합된 접합물을 고수율로 제조하는 방법 | |
CN117427179A (zh) | 一种人尿激肽原酶的化学修饰物 | |
US20150329601A1 (en) | Methoxypolyethyleneglycol succinimidyl propionate modified recombinant Ganoderma Lucidum immunoregulatory protein, preparing method and application thereof | |
UA73468C2 (en) | Conjugate of erythropoietin, compositions containing it, and methods for prevention and/or treatment of diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1136838 Country of ref document: HK |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1136838 Country of ref document: HK |
|
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047 Patentee after: JIANGSU HANSOH PHARMACEUTICAL GROUP Co.,Ltd. Address before: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047 Patentee before: Jiangsu best Pharmaceutical Co.,Ltd. Address after: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047 Patentee after: Jiangsu best Pharmaceutical Co.,Ltd. Address before: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047 Patentee before: JIANGSU HANSOH PHARMACEUTICAL Co.,Ltd. |